DEF: Aprea Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Aprea Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on director elections, auditor ratification, executive compensation, and other matters.

Summary

• Aprea Therapeutics has scheduled its 2025 Annual Meeting of Stockholders for June 5, 2025, at 9:00 a.m. Eastern Time, to be held virtually.
• Stockholders of record as of April 10, 2025, are eligible to vote.
• The meeting will address the election of three Class III directors (Jean-Pierre Bizzari, Oren Gilad, and John B. Henneman III) for terms expiring in 2028.
• Stockholders will also vote to ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm for the 2025 fiscal year.
• An advisory vote on the compensation of named executive officers and the frequency of future 'say on pay' votes will also take place.
• The Board of Directors recommends voting FOR the election of the director nominees, FOR the ratification of EisnerAmper LLP, FOR the advisory vote on executive compensation, and FOR holding future advisory votes on executive compensation every year.
• As of April 10, 2025, there were 5,525,172 shares of common stock outstanding, each entitled to one vote.

Sentiment

Score: 7

Explanation: The document is a routine proxy statement, indicating a neutral to slightly positive sentiment due to the standard corporate governance processes being followed.

Positives

• The Board of Directors is actively engaged in corporate governance, as evidenced by the various committees and their responsibilities.
• Stockholders have the opportunity to provide input on executive compensation through advisory votes.
• The company is committed to transparency by providing detailed information on director compensation and related party transactions.
• The virtual meeting format allows for broader stockholder participation regardless of location.

Negatives

• The classified board structure with staggered three-year terms may delay or prevent a change of management or control of the company.
• The document does not contain any negative information.

Risks

• The document does not contain any risk information.

Future Outlook

The document outlines the matters to be voted on at the upcoming Annual Meeting, providing a glimpse into the company's governance and operational focus for the coming year.

Management Comments

• Oren Gilad, Ph.D., Chief Executive Officer, expressed appreciation for stockholders' ongoing support of Aprea Therapeutics.

Industry Context

As a clinical-stage biopharmaceutical company, Aprea Therapeutics' annual meeting and proxy statement reflect standard corporate governance practices within the biotech industry, including executive compensation, board composition, and auditor oversight.

Comparison to Industry Standards

• The proxy statement includes standard elements such as director biographies, committee charters, and executive compensation disclosures, aligning with SEC requirements and industry norms.
• The company's approach to board independence and committee composition is consistent with Nasdaq listing standards.
• The use of a virtual annual meeting format is increasingly common among publicly traded companies to enhance accessibility for stockholders.

Stakeholder Impact

• Stockholders will have the opportunity to influence the company's direction through their votes on key proposals.
• The outcome of the votes will impact the composition of the Board of Directors and the oversight of executive compensation.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 5, 2025, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, Aprea Therapeutics